PHARMACY

NCPA and others will need to bring freshman Congress class up to speed in record time

BY Michael Johnsen

The National Community Pharmacists Association last week noted that language in the "fiscal cliff" legislation that averted the worst of potential tax consequences for individuals nonetheless had a chance to negatively impact diabetics who buy their supplies from their local community pharmacy. 

So while Wall Street was rocking and rolling last week on the news that the economy wouldn’t be hurdling down the same road traveled by Thelma & Louise, at least not yet, the news brought to light another issue — the new Congress, with its freshman class of 97 legislators, will be addressing plenty of mature problems — such as the consequences of not exempting independent pharmacies from competitive bidding when it comes to durable medical equipment and diabetes supplies. 

So here’s a quick refresher, courtesy of the Office of Inspector General. It’s a document released on Nov. 7, 2012 that "appears to reinforce three things about mail order health care: 1) it’s not for everyone; 2) it results in wasteful “auto-shipping” of medical products; and 3) it’s more expensive than advertised," according to an article published in NCPA’s The Dose

In a nutshell, the OIG found that the use of non-mail order sources for diabetic testing supplies increased by 33% when competitive bidding was implemented. Why? Well, 10% switched because they didn’t like mail, according to the report in The Dose, and 5% switched because mail order sent them supplies they never really needed in the first place. 

In the event that you are a show-me person, and would like to see what kind of waste of diabetes supplies can accumulate via mail order, check out this YouTube video posted by Oklahoma pharmacist Todd Pendergraft of Broken Arrow Family Drug.  

Lobbying groups like NCPA and others are going to have their work cut out for them this year as they bring all the freshman Congress leaders up to speed on pertinent health delivery issues. And time is of the essence, with states and employers preparing for the implementation of the lion’s share of healthcare reform less than one year from now. 

What are your key issues? When targeting the 2013 freshman class, what should NCPA’s government relations team be focusing on?

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA approves new delivery method for MS drug

BY Alaric DeArment

NEW YORK — The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.

Pfizer and EMD Serono announced the approval of Rebif Rebidose (interferon beta-1a), a single-use auto-injector for self-administering Rebif, used to treat relapsing forms of MS. EMD Serono is the U.S. division of German drug maker Merck KGaA, so-named to avoid confusion with U.S.-based Merck & Co.

"We are pleased to announce the FDA has approved Rebif Rebidose, which provides people living with relapsing MS another option to meet their injection needs," EMD Serono president James Hoyes said. "The introduction of Rebif Rebidose underscores our commitment to the MS community and to our investment in the development of delivery devices to assist with ease of use and support those living with MS."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Novo Nordisk appoints Curtis Oltmans as corporate VP, general counsel for legal and quality affairs

BY Alaric DeArment

PRINCETON, N.J. — Novo Nordisk has appointed Curtis Oltmans as its corporate VP and general counsel for legal and quality affairs, the company said Friday.

In the new role, for which he will also join the company’s U.S. executive team, Oltmans will be handle issues like law, quality, intellectual property, grants and philanthropy for the Danish drug maker’s North American business.

As VP and deputy general counsel for the company, Oltmans led the legal affairs team and was tapped in 2010 to lead the company’s Native American Health Initiative, a project to build sustainable diabetes care and education programs with the Rosebud Sioux Tribe in Rosebud, S.D.

"Curt has used his extensive knowledge of the pharmaceutical industry to make significant contributions during his tenure so far at Novo Nordisk," Novo Nordisk president Jerzy Gruhn said. "He has led our legal team through a number of significant milestones, along with overseeing an important social responsibility effort for the Native American community."

Oltmans, who began working for Novo Nordisk in 2005, previously worked for Eli Lilly and the legal firm Shook, Hardy & Bacon.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES